Cord Blood America Acquires CureSource Assets, Umbilical Cord Blood Storage Company Headquartered in South Carolina.LOS ANGELES and CHARLESTON, S.C., Aug. 21 /PRNewswire-FirstCall/ -- Cord Blood cord blood
Blood present in the umbilical vessels at the time of delivery. America, Inc. (BULLETIN BOARD: CBAI CBAI The Community Bankers Association of Illinois
CBAI Contract Bridge Association of Ireland (UK) ) , the umbilical cord blood umbilical cord blood Transplantation A source of primitive and stem cells that can be used to reconstitute BM destroyed by aplastic anemia or by RT or chemotherapy for CA, lymphoproliferative malignancies. See Bone marrow transplantation, Stem cell therapy. stem cell preservation company (http://www.cordblood-america.com/) focused on bringing the life saving potential of stem cells to families in all 50 states and internationally, today announced that it has acquired the assets of CureSource, Inc., a private umbilical cord blood storage company headquartered in Charleston, South Carolina.
"This is our third acquisition as we continue to grow Cord Blood America into a major umbilical cord blood storage company worldwide," said Matthew Schissler, Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. . Details of the transaction were not made public. CureSource(TM), founded in 2003, is known for offering affordable service and for the careful attention it provides families storing their umbilical cords for possible future medical use.
CureSource(TM) currently serves families throughout the U.S. "We are pleased with this transaction because Cord Blood America believes, as we do, in affordable service and taking care of the needs of the families," said CureSource Chairman Donald P. DeLuca, Sr.
"The CureSource transaction provides us with additional customers, and with a new territory to broaden the sales channels that the CureSource staff vigorously developed. This transaction extends Cord Blood America's geographic reach and ensures that we are one of the companies coming out on top as the industry consolidates," Mr. Schissler said. "We view this as another major positive for our Company and our investors."
About Cord Blood America
Cord Blood America (BULLETIN BOARD: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells cord blood stem cells Umbilical cord blood Hematology A therapeutic 'agent' containing concentrated hematopoietic stem cells for Pts with BM depleted–'wiped out' by disease; they are transfused into HLA-identical siblings and used to reconstitute the BM of offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (BULLETIN BOARD: CBAI) , visit our website at http://www.corcell.com/. For investor information, visit http://www.cordblood-america.com/.
Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. We use words such as "anticipate," "believe," "expect," "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments Medical researchers believe that stem cell treatments have the potential to change the face of human disease and alleviate suffering. A number of stem cell treatments already exist, although most are still experimental and/or costly, with the notable exception of bone marrow , and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.
CONTACT: Paul Knopick E & E Communications 949/707-5365 firstname.lastname@example.org
CONTACT: Paul Knopick of E & E Communications, +1-949-707-5365, email@example.com, for Cord Blood America, Inc.
Web site: http://www.corcell.com/ http://www.cordblood-america.com/